Shots:
Cerevance to receive a $25M up front & is eligible to receive ~$1.1B in development & commercial milestones along with royalties on sales of approved products that emerge from the collaboration
The collaboration will use Cerevance’s NETSseq technology platform to identify novel targets for AD. Additionally, Cerevance will out-license one discovery-stage program to Merck
Cerevance’s NETSseq technology platform has isolated & enabled for investigation of specific cell populations in the post-mortem, healthy & sick human brain tissue samples across a range of ages & brain regions. The platform also identifies new therapeutic targets to improve neuronal circuitry or decrease the progression of the disease
Ref: Cerevance | Image: Merck
